Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Between 2022 and 2026, GLP-1 use among people aged 1325 seeking obesity treatment increased from 88.2% to 96.1% and outpaced metabolic and bariatric surgery (MBS) use, which saw a decline from 11.6% to 3.7%
Germany Focuses on Private Sector Treatment Access Demand for obesity GLP-1 treatment in Germany is projected to grow at a CAGR of 19.6%, constrained by statutory health insurance exclusions for anti-obesity medications that limit public reimbursement
Women who are considering tirzepatide while breastfeeding should know that hydration demands increase significantly during lactation
Pale yellow is the target
US$ 27.94
US$ 20.28
US$ 21.15
US$ 24.59
US$ 21.06
US$ 21.77
US$ 24.71
